Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Jazz Pharmaceuticals PLC has received a consensus rating of "Moderate Buy" from 17 research firms, with an average 12-month price target of approximately $178.93.
• Insider trading activities indicate Director Bruce C. Cozadd sold 6,000 shares at an average price of $128.62, decreasing his holdings by 1.38%.
• Jazz Pharmaceuticals reported a quarterly loss of ($8.25) earnings per share, missing analyst estimates by $2.64, while achieving a revenue of $1.05 billion.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seventeen research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $178.9333.

A number of equities analysts have issued reports on JAZZ shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. The Goldman Sachs Group lifted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a report on Wednesday, September 24th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Jazz Pharmaceuticals in a report on Saturday, September 27th.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares of the company's stock, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company's stock valued at $86,000 after acquiring an additional 154 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Jazz Pharmaceuticals by 1.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,383 shares of the specialty pharmaceutical company's stock valued at $1,314,000 after acquiring an additional 201 shares during the period. Thrivent Financial for Lutherans grew its stake in Jazz Pharmaceuticals by 38.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 19,720 shares of the specialty pharmaceutical company's stock valued at $2,093,000 after acquiring an additional 5,440 shares during the period. Marex Group plc acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $610,000. Finally, State of Wyoming grew its stake in Jazz Pharmaceuticals by 21.4% in the 2nd quarter. State of Wyoming now owns 4,029 shares of the specialty pharmaceutical company's stock valued at $428,000 after acquiring an additional 709 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.7%

NASDAQ:JAZZ opened at $139.48 on Friday. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock has a market capitalization of $8.46 billion, a P/E ratio of -20.73, a P/E/G ratio of 8.65 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company's 50-day simple moving average is $123.75 and its 200-day simple moving average is $115.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the business posted $5.30 earnings per share. The firm's quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.